Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis

Journal of Immunology

Volumn 193, Issue 6, 2014, Pages 2911-2918

  Orr, Mark T ^a   Ireton, Gregory C ^a   Beebe, Elyse A ^a   Huang, Po Wei D ^a   Reese, Valerie A ^a   Argilla, David ^a   Coler, Rhea N ^a,b   Reed, Steven G ^a,b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD40 LIGAND; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; EPITOPE; HYBRID PROTEIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; EMULSION; FEMALE; IMMUNOGENICITY; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; ANIMAL; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; IMMUNODOMINANT EPITOPES; MICE; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT FUSION PROTEINS; TH1 CELLS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84921629016     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401103     Document Type: Article

References (47)

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva.
2. Abubakar, I., L. Pimpin, C. Ariti, R. Beynon, P. Mangtani, J. A. Sterne, P. E. Fine, P. G. Smith, M. Lipman, D. Elliman, et al. 2013. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol. Assess. 17: 1-372, v-vi.
3. Hart, P. D., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. BMJ 2: 293-295.
4. Baily, G. V. 1980. Tuberculosis prevention Trial, Madras. Indian J. Med. Res. 72 (Suppl.): 1-74.
5. Brennan, M. J., and J. Thole. 2012. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb.) 92(Suppl. 1): S6-S13.
6. Checkley, A. M., and H. McShane. 2011. Tuberculosis vaccines: progress and challenges. Trends Pharmacol. Sci. 32: 601-606.
7. Flynn, J. L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immunol. 19: 93-129.
8. Cooper, A. M. 2009. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27: 393-422.
9. Bertholet, S., G. C. Ireton, D. J. Ordway, H. P. Windish, S. O. Pine, M. Kahn, T. Phan, I. M. Orme, T. S. Vedvick, S. L. Baldwin, et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis. Sci. Transl. Med. 2: 53ra74.
10. Dietrich, J., C. Aagaard, R. Leah, A. W. Olsen, A. Stryhn, T. M. Doherty, and P. Andersen. 2005. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 174: 6332-6339.
11. Hubbard, R. D., C. M. Flory, and F. M. Collins. 1992. Immunization of mice with mycobacterial culture filtrate proteins. Clin. Exp. Immunol. 87: 94-98.
12. McShane, H., and A. Hill. 2005. Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 7: 962-967.
13. Reed, S. G., R. N. Coler, W. Dalemans, E. V. Tan, E. C. DeLa Cruz, R. J. Basaraba, I. M. Orme, Y. A. Skeiky, M. R. Alderson, K. D. Cowgill, et al. 2009. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. [Published erratum appears in 2009 Proc. Natl. Acad. Sci. USA 106: 7678.] Proc. Natl. Acad. Sci. USA 106: 2301-2306.
14. Skeiky, Y. A., M. R. Alderson, P. J. Ovendale, J. A. Guderian, L. Brandt, D. C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I. M. Orme, and S. G. Reed. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172: 7618-7628.
15. Aagaard, C., T. Hoang, J. Dietrich, P. J. Cardona, A. Izzo, G. Dolganov, G. K. Schoolnik, J. P. Cassidy, R. Billeskov, and P. Andersen. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17: 189-194.
16. Dietrich, J., R. Billeskov, T. M. Doherty, and P. Andersen. 2007. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J. Immunol. 178: 3721-3730.
17. Knudsen, N. P., S. Nørskov-Lauritsen, G. M. Dolganov, G. K. Schoolnik, T. Lindenstrøm, P. Andersen, E. M. Agger, and C. Aagaard. 2014. Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc. Natl. Acad. Sci. USA 111: 1096-1101.
18. Bertholet, S., G. C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E. M. Laughlin, S. L. Baldwin, T. S. Vedvick, R. N. Coler, and S. G. Reed. 2008. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181: 7948-7957.
19. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171: 1602-1609.
20. Comas, I., J. Chakravartti, P. M. Small, J. Galagan, S. Niemann, K. Kremer, J. D. Ernst, and S. Gagneux. 2010. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 42: 498-503.
21. Copin, R., M. Coscollá, S. N. Seiffert, G. Bothamley, J. Sutherland, G. Mbayo, S. Gagneux, and J. D. Ernst. 2014. Sequence diversity in the pe-pgrs genes of Mycobacterium tuberculosis is independent of human T cell recognition. MBio 5: e00960-e13.
22. Ernst, J. D. 2012. The immunological life cycle of tuberculosis. Nat. Rev. Immunol. 12: 581-591.
23. Sutherland, J. S., I. M. Adetifa, P. C. Hill, R. A. Adegbola, and M. O. Ota. 2009. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39: 723-729.
24. Caccamo, N., G. Guggino, S. A. Joosten, G. Gelsomino, P. Di Carlo, L. Titone, D. Galati, M. Bocchino, A. Matarese, A. Salerno, et al. 2010. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40: 2211-2220.
25. Orme, I. M. 2011. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol. 6: 161-177.
26. Ireton, G. C., R. Greenwald, H. Liang, J. Esfandiari, K. P. Lyashchenko, and S. G. Reed. 2010. Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin. Vaccine Immunol. 17: 1539-1547.
27. Lalvani, A., S. Sridhar, and C. F. von Reyn. 2013. Tuberculosis vaccines: time to reset the paradigm? Thorax 68: 1092-1094.
28. Orme, I. M. 2013. Vaccine development for tuberculosis: current progress. Drugs 73: 1015-1024.
29. Coler, R. N., S. Bertholet, M. Moutaftsi, J. A. Guderian, H. P. Windish, S. L. Baldwin, E. M. Laughlin, M. S. Duthie, C. B. Fox, D. Carter, et al. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6: e16333.
30. Orr, M. T., C. B. Fox, S. L. Baldwin, S. J. Sivananthan, E. Lucas, S. Lin, T. Phan, J. J. Moon, T. S. Vedvick, S. G. Reed, and R. N. Coler. 2013. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J. Control. Release 172: 190-200.
31. Mukamolova, G. V., O. A. Turapov, D. I. Young, A. S. Kaprelyants, D. B. Kell, and M. Young. 2002. A family of autocrine growth factors in Mycobacterium tuberculosis. Mol. Microbiol. 46: 623-635.
32. Aagaard, C., T. T. Hoang, A. Izzo, R. Billeskov, J. Troudt, K. Arnett, A. Keyser, T. Elvang, P. Andersen, and J. Dietrich. 2009. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS ONE 4: e5930.
33. Via, L. E., P. L. Lin, S. M. Ray, J. Carrillo, S. S. Allen, S. Y. Eum, K. Taylor, E. Klein, U. Manjunatha, J. Gonzales, et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76: 2333-2340.
34. Lindestam Arlehamn, C. S., A. Gerasimova, F. Mele, R. Henderson, J. Swann, J. A. Greenbaum, Y. Kim, J. Sidney, E. A. James, R. Taplitz, et al. 2013. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog. 9: e1003130.
35. Harris, S. A., J. Meyer, I. Satti, L. Marsay, I. D. Poulton, R. Tanner, A. M. Minassian, H. A. Fletcher, and H. McShane. 2014. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J. Infect. Dis. 209: 1259-1268.
36. Shultz, L. D., M. A. Brehm, J. V. Garcia-Martinez, and D. L. Greiner. 2012. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12: 786-798.
37. Billerbeck, E., J. A. Horwitz, R. N. Labitt, B. M. Donovan, K. Vega, W. C. Budell, G. C. Koo, C. M. Rice, and A. Ploss. 2013. Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice. J. Immunol. 191: 1753-1764.
38. Danner, R., S. N. Chaudhari, J. Rosenberger, J. Surls, T. L. Richie, T. D. Brumeanu, and S. Casares. 2011. Expression of HLA class II molecules in humanized NOD. Rag1KO. IL2RgcKO mice is critical for development and function of human T and B cells. PLoS ONE 6: e19826.
39. Shultz, L. D., Y. Saito, Y. Najima, S. Tanaka, T. Ochi, M. Tomizawa, T. Doi, A. Sone, N. Suzuki, H. Fujiwara, et al. 2010. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc. Natl. Acad. Sci. USA 107: 13022-13027.
40. Lee, J., M. A. Brehm, D. Greiner, L. D. Shultz, and H. Kornfeld. 2013. Engrafted human cells generate adaptive immune responses to Mycobacterium bovis BCG infection in humanized mice. BMC Immunol. 14: 53.
41. Calderon, V. E., G. Valbuena, Y. Goez, B. M. Judy, M. B. Huante, P. Sutjita, R. K. Johnston, D. M. Estes, R. L. Hunter, J. K. Actor, et al. 2013. A humanized mouse model of tuberculosis. PLoS ONE 8: e63331.
42. Heuts, F., D. Gavier-Widén, B. Carow, J. Juarez, H. Wigzell, and M. E. Rottenberg. 2013. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc. Natl. Acad. Sci. USA 110: 6482-6487.
43. Tameris, M. D., M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, et al; MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
44. Ota, M. O., A. A. Odutola, P. K. Owiafe, S. Donkor, O. A. Owolabi, N. J. Brittain, N. Williams, S. Rowland-Jones, A. V. Hill, R. A. Adegbola, and H. McShane. 2011. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci. Transl. Med. 3: 88ra56.
45. Brookes, R. H., P. C. Hill, P. K. Owiafe, H. B. Ibanga, D. J. Jeffries, S. A. Donkor, H. A. Fletcher, A. S. Hammond, C. Lienhardt, R. A. Adegbola, et al. 2008. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS ONE 3: e2921.
46. Hawkridge, T., T. J. Scriba, S. Gelderbloem, E. Smit, M. Tameris, S. Moyo, T. Lang, A. Veldsman, M. Hatherill, Lv. Merwe, et al. 2008. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198: 544-552.
47. McShane, H., and A. Williams. 2014. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis (Edinb.) 94: 105-110.